Related Experiment Video
Updated: Jan 31, 2026
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Next generation designer virus-like particle vaccines for dengue
Rahul Shukla1, Viswanathan Ramasamy1, Ravi Kant Rajpoot1
1a Recombinant Gene Products Group, Molecular Medicine Division , International Centre for Genetic Engineering & Biotechnology , New Delhi , India.
Introduction:
A safe and efficacious vaccine for dengue continues to be an unmet public health need. The recent licensing of a dengue vaccine (Dengvaxia) developed by Sanofi has brought to the fore the safety issue of vaccine-induced infection enhancement.
Areas Covered:
This article focuses on two new yeast-produced tetravalent dengue envelope domain III-displaying virus-like particulate vaccine candidates reported in early 2018 and reviews the rationale underlying their design, and pre-clinical data which suggest that these may offer promising alternate options.
Expert Commentary:
These are the only vaccine candidates so far to have demonstrated the induction of primarily serotype-specific neutralizing antibodies to all dengue virus serotypes in experimental animals. Interestingly, these antibodies lack infection-enhancing potential when evaluated using the AG129 mouse model.
Related Concept Videos
01:51Vaccinations
00:50What are Viruses?
03:37Subatomic Particles
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:01Group Design
02:10The Nucleosome Core Particle
The paradox
Nucleosomes, paradoxically, perform two opposite functions simultaneously. On the one hand, their main responsibility is to protect the delicate DNA strands from physical damage and help achieve a higher compaction ratio. While on the other hand, they must allow polymerase enzymes to access DNA...